StockNews.com Initiates Coverage on Cutera (NASDAQ:CUTR)

Stock analysts at StockNews.com initiated coverage on shares of Cutera (NASDAQ:CUTR) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Trading Down 5.1 %

Shares of NASDAQ:CUTR opened at $0.43 on Wednesday. The stock has a fifty day simple moving average of $0.40 and a two-hundred day simple moving average of $0.68. Cutera has a 12-month low of $0.28 and a 12-month high of $3.18. The stock has a market capitalization of $8.68 million, a price-to-earnings ratio of -0.07 and a beta of 1.31.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Thursday, November 7th. The medical device company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.98). The company had revenue of $32.50 million for the quarter, compared to the consensus estimate of $32.57 million. During the same quarter last year, the business earned ($2.22) earnings per share. As a group, equities research analysts predict that Cutera will post -5.78 EPS for the current year.

Institutional Trading of Cutera

An institutional investor recently raised its position in Cutera stock. Squarepoint Ops LLC lifted its holdings in shares of Cutera, Inc. (NASDAQ:CUTR) by 164.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 113,964 shares of the medical device company’s stock after buying an additional 70,870 shares during the period. Squarepoint Ops LLC owned approximately 0.57% of Cutera worth $172,000 at the end of the most recent reporting period. Institutional investors own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.